VOXR:NASDAQVox Royalty Corp. Analysis
Data as of 2026-06-14 - not real-time
$5.18
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
VOXR is trading at $5.18, well below its DCF fair value of $9.42, implying roughly a 50% upside. The 20‑day SMA of 5.64 sits just above the 50‑day SMA of 5.61, supporting a modest bullish bias, while the 200‑day SMA of 4.96 remains well under the current price. Momentum indicators are mixed: RSI is at 43, indicating neutral pressure, and the MACD histogram is negative, signaling short‑term bearish momentum. Volatility is high at 64.5% over the past 30 days and beta is elevated at 1.84, suggesting the stock moves more aggressively than the market. Fundamentals are solid with a PE of 11.5, a dividend yield of 1.16%, and a payout ratio under 12%, all backed by strong cash generation and zero debt. Recent material news highlights record Q1 results, raised guidance, and a declared quarterly dividend, reinforcing confidence in cash flow stability.
The royalty‑focused business model provides exposure to a diversified portfolio of 70 precious‑metal assets across six countries, mitigating single‑mine risk. With a low debt‑to‑equity ratio, robust ROE of 35%, and free cash flow exceeding $17 M, the company appears capable of sustaining its dividend and funding growth. Analyst consensus leans toward a “strong buy” with a mean target price near $7.8, aligning with the upside potential indicated by the DCF. Given the blend of undervaluation, solid fundamentals, and dividend appeal, the stock is positioned favorably for medium‑ to long‑term investors, while short‑term traders should watch the bearish MACD signal and high volatility.
The royalty‑focused business model provides exposure to a diversified portfolio of 70 precious‑metal assets across six countries, mitigating single‑mine risk. With a low debt‑to‑equity ratio, robust ROE of 35%, and free cash flow exceeding $17 M, the company appears capable of sustaining its dividend and funding growth. Analyst consensus leans toward a “strong buy” with a mean target price near $7.8, aligning with the upside potential indicated by the DCF. Given the blend of undervaluation, solid fundamentals, and dividend appeal, the stock is positioned favorably for medium‑ to long‑term investors, while short‑term traders should watch the bearish MACD signal and high volatility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Negative MACD histogram indicating short‑term bearish momentum
- High 30‑day volatility and elevated beta
- Current price near stable support level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued relative to DCF fair value and analyst targets
- Strong cash flow and zero debt supporting dividend sustainability
- Diversified royalty portfolio reducing operational risk
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Consistent dividend yield with low payout ratio
- High ROE and stable operating margins
- Exposure to precious‑metal demand across multiple geographies
Key Metrics & Analysis
Financial Health
Revenue Growth498.30%
Profit Margin102.50%
P/E Ratio11.5
ROE34.88%
ROA20.16%
P/B Ratio2.7
Op. Cash Flow$24.9M
Free Cash Flow$17.5M
Technical Analysis
TrendBullish
RSI43.0
Support$4.66
Resistance$6.50
MA 20$5.64
MA 50$5.61
MA 200$4.96
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value$9.42
Target Price$7.78
Upside/Downside50.19%
GradeUndervalued
TypeValue
Dividend Yield1.16%
Risk Assessment
Beta1.84
Volatility64.54%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.